| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 239 |
| 1 | BEVACIZUMAB | 157 |
| 2 | CARBOPLATIN | 102 |
| 3 | METHOTREXATE SODIUM | 94 |
| 4 | DEXAMETHASONE | 93 |
| 5 | DEXAMETHASONE 1.5 MG | 93 |
| 6 | PANTOPRAZOLE | 93 |
| 7 | CLOZAPINE | 92 |
| 8 | OMEPRAZOLE MAGNESIUM | 92 |
| 9 | INFLIXIMAB | 91 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | L DOPA | 14 | 0.0522 |
| 1 | NEOSTIGMINE METHYLSULFATE | 15 | 0.0348 |
| 2 | PAPAVERINE HYDROCHLORIDE | 1 | 0.0098 |
| 3 | SODIUM CHLORIDE, CALCIUM CHLORIDE, AND POTASSIUM CHLORIDE | 1 | 0.0084 |
| 4 | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | 1 | 0.0076 |
| 5 | LOXAPINE | 29 | 0.0073 |
| 6 | TRIHEXYPHENIDYL HYDROCHLORIDE | 7 | 0.0069 |
| 7 | PRUCALOPRIDE SUCCINATE | 2 | 0.0057 |
| 8 | CARBIDOPA TABLETS | 17 | 0.0056 |
| 9 | INTERLEUKIN-10 | 2 | 0.0056 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 298 |
| 1 | Nucleoside Metabolic Inhibitor [EPC] | 212 |
| 2 | Platinum-based Drug [EPC] | 205 |
| 3 | Atypical Antipsychotic [EPC] | 191 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 165 |
| 5 | Tumor Necrosis Factor Blocker [EPC] | 158 |
| 6 | Proton Pump Inhibitor [EPC] | 149 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 144 |
| 8 | Benzodiazepine [EPC] | 126 |
| 9 | Kinase Inhibitor [EPC] | 100 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 22 | 0.0025 |
| 1 | Cholinesterase Inhibitor [EPC] | 42 | 0.0022 |
| 2 | GLP-2 Analog [EPC] | 24 | 0.0018 |
| 3 | Lymphocyte Growth Factor [EPC] | 2 | 0.0016 |
| 4 | CD33-directed Immunoconjugate [EPC] | 5 | 0.0014 |
| 5 | Aromatic Amino Acid Decarboxylation Inhibitor [EPC] | 35 | 0.0012 |
| 6 | Epidermal Growth Factor Receptor Antagonist [EPC] | 58 | 0.0012 |
| 7 | Human Blood Coagulation Factor [EPC] | 1 | 0.0012 |
| 8 | Stimulant Laxative [EPC] | 16 | 0.0011 |
| 9 | Dopamine-2 Receptor Antagonist [EPC] | 8 | 0.0010 |